Exscientia creates first drug using AI
pharmafile | January 31, 2020 | News story | Medical Communications | AI, AI healthcare, ai pharma
Exscientia has created a new OCD drug using artificial intelligence to sift through potential compounds, checking them against a huge database of parameters.
The drug, called DSP-1181, was created in collaboration with Sumitomo Dainippon Pharma, and cut the traditional drug development time from 4.5 years to just 12 months.
Toru Kimura, Senior Executive Officer and Senior Executive Research Director of Sumitomo Dainippon Pharma, said: “We are very excited with the results of the joint research that resulted in the development of candidate compounds in a very short time. Exscientia’s sophisticated AI drug discovery technologies combined with our company’s deep experience in monoamine GPCR drug discovery, allowed us to work synergistically, delivering a highly successful outcome. We will continue to work hard to make this clinical study a success so that it may deliver new benefits to patients as soon as possible.”
DSP-1181 was created through joint research by Sumitomo Dainippon Pharma and Exscientia, with Sumitomo Dainippon Pharma providing its experience and knowledge in monoamine GPCR drug discovery and Exscientia applying its Centaur Chemist Artificial Intelligence platform for drug discovery.
The first drug will go through Phase 1 trials in Japan and Exscientia hopes to have another treatment for either cancer or cardiovascular disease by the end of the year.
Andrew Hopkins, CEO of Exscientia, said: “We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery. This project’s rapid success was through strong alignment of the integrated knowledge and experiences in chemistry and pharmacology on monoamine GPCR drug discovery at Sumitomo Dainippon Pharma with our AI technologies. We are proud that our AI drug discovery platform Centaur Chemist has contributed to generate DSP-1181 and look forward to its progression as a treatment for obsessive-compulsive disorder.”
Conor Kavanagh
Related Content
Liverpool launches £20m lab for infectious disease drug discovery
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Bioptimus partners with Cancer Research Horizons to expand AI cancer data set
Bioptimus has partnered with Cancer Research Horizons, the innovation arm of Cancer Research UK, to …
